Sartorius Stedim Biotech Extends PAT Portfolio with Innovative Sensors for Flow Rate Measurement
![](/46/pdcnewsitem/03/42/68/8Rj9yttVMSGeGCr.jpg)
Sartorius Stedim Biotech (SSB) has entered into a global development co-operation agreement with the flow measurement company em-tec. This highly specialized firm provides non-invasive flow engineering solutions for blood vessels and flexible tubing. Such technology designed by em-tec is used in the biopharmaceutical industry, among other sectors, in many process steps for accurate measurement of flow rates and mass balances. In particular, this technology is used in downstream processes, such as virus inactivation, as well as in ultrafiltration and diafiltration.
As part of this co-operation, the technology base of em-tec will be extended by jointly developed single-use components, such as FlowTube. Sartorius will exclusively market these as applications and distribute them worldwide as private label products under the brand name of BioPAT Flow.
SSB has continuously expanded its process analytics portfolio over the past years in the area of sensor technology to enable non-invasive, real-time measurement of critical process parameters, such as pH, dissolved oxygen, temperature, glucose, lactate and biomass. The new flow sensors are important new components that have been added to this portfolio. BioPAT Flow permits precise, reproducible data to be collected on flow rates and mass balances without coming in contact with the medium during measurement.
“The sensors make our downstream unit operations even more intelligent, significantly increasing the level of automation. Integrated into our system solutions, these sensors are powerful tools for designing robust biopharmaceutical processes and further optimizing them,” states Stefan Schlack, Senior Vice President of Marketing at SSB.
Dr Hannspeter Schubert, managing director of em-tec, comments: “SSB is among the top global suppliers in automated bioprocess solutions and has a strong globally based sales and marketing network. We are pleased that Sartorius has opted for our basic technology of non-invasive flow rate measurement. The use of our sensors in fully integrated, automated bioprocesses represents an ideal application field and an innovative technological advance for us.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance